TrialArchives of dermatological research2024
Ritlecitinib, a JAK3/TEC family kinase inhibitor, stabilizes active lesions and repigments stable lesions in vitiligo.
Yuji Yamaguchi et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
9 papers cite it
this paperpooled itcites it